Navigation Links
Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting

de effects such as sedation and withdrawal. The precise mechanism of action is unknown, however, GABA is believed to be an important neurotransmitter in the brain that may be disrupted in people who stutter. Pagoclone enhances the activity in GABA circuits in the brain and thus may help restore more normal function in speech areas of the brain.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male hypogonadism, all of which are currently marketed, as well as SUPPRELIN(R) LA, which was recently approved for central precocious puberty. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include SANCTURA XR(TM), the once-daily formulation of SANCTURA, VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering.

Forward-Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R) and VANTAS(R); the early state of products under developme
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Indevus Reports Positive Data From Phase III NEBIDO Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:3/3/2015)... Fla. , March 3, 2015 ... pleased to announce the hiring of Brian ... to lead business development efforts and build relationships ... of experience in software development, sales, and sales ... enterprise software applications. iTraycer is a comprehensive inventory ...
(Date:3/3/2015)... -- Dr. Cummins is known for being one of ... In addition to performing cosmetic and hand surgery at ... Cummins now offers advanced laser tattoo removal treatments at ... performs all treatments himself using the industry-leading Astanza Duality ... order to help people take back control over the ...
(Date:3/3/2015)... --   Clinical trials at ... Publications in peer reviewed journals Gastrointestinal Endoscopy ... diagnostic value of confocal laser endomicroscopy in treatment of ... across Asia   ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today ...
Breaking Medicine Technology:Medical Tracking Solutions, Inc. Hires New SVP, Sales 2Surgeon Owned And Operated Louisville Tattoo Removal Offers Astanza Duality Laser Treatments 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4
... Disease Research Interchange, a Philadelphia-based national human tissue center ... awarded a $3.59 million subcontract from the National Institutes ... (Genotype-Tissue Expression). The funds for the 30-month project are ... NCI (the National Cancer Institute), NIMH (the National Institute ...
... FOUNTAIN HILLS, Ariz., Oct. 13 Sunridge International (OTC ... received an order for additional inventory from New Amsterdam ...  New Amsterdam personnel are currently on a two-week marketing ...  New Amsterdam,s personnel is accompanied by Leo D. Bores ...
Cached Medicine Technology:NDRI Has Been Awarded $3.59 Million From the National Institutes of Health, 'The Directors Common Fund' to Provide Human Tissue for 'GTEx,' the New Genotype-Tissue Expression Project 2NDRI Has Been Awarded $3.59 Million From the National Institutes of Health, 'The Directors Common Fund' to Provide Human Tissue for 'GTEx,' the New Genotype-Tissue Expression Project 3NDRI Has Been Awarded $3.59 Million From the National Institutes of Health, 'The Directors Common Fund' to Provide Human Tissue for 'GTEx,' the New Genotype-Tissue Expression Project 4
(Date:3/3/2015)... The human augmentation market is mainly driven ... wearable augmentation sector is predicted to outpace the in-built ... years. , The eye-wear sector dominates the North ... of new products launches in the region. Furthermore, strong ... as well as the rising demand for advantageous products ...
(Date:3/3/2015)... While it is clear that the prospect of reduced ... are signing up to UBI policies, more mature audiences ... Due to current regulations, the application of UBI in ... full capability is starting to be realised in the ... services are at the top of the value-added services ...
(Date:3/3/2015)... 03, 2015 DePuy Pinnacle hip ... version of the artificial hip system caused recipients ... move forward in the federal multidistrict litigation underway ... According to the most recent Master Case List ... 7,350 Pinnacle hip replacement lawsuits are now pending ...
(Date:3/3/2015)... BC (PRWEB) March 03, 2015 The ... doubled since 1984 to about 15%. This increases to ... old. (Bushnik T, Cook JL, Yuzpe AA, et al. ... 2012; 27: 738-46). Dr. Jason Hitkari, a reproductive endocrinologist ... a doctor of TCM and clinical director and founder ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 ... is estimated to grow from $1,224.6 million ... 6.71% between 2014 and 2019. , Browse ... delivery network market for an analysis of ... of various tables and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html ...
Breaking Medicine News(10 mins):Health News:Human Augmentation Market to Pose 43.5% CAGR Through 2020, States MarketsandMarkets in its New Research Study Now Available at MarketPublishers.com 2Health News:TU-Automotive: Wawanesa Insurance to Discuss How UBI Can Produce Happy, Loyal Customers 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 4Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 2Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 3Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 4Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3
... HOPKINTON, Mass., Sept. 14 EMC Corporation (NYSE: ... infrastructure solutions, today announced that eClinicalWorks, a market leader ... provider customers, has consolidated and enhanced security of its ... As a result, eClinicalWorks has successfully managed rapid business ...
... , , ITASCA, Ill., Sept. 14 ... the JEWEL-OSCO grocery checkout. , , Starting today ... pharmacy will receive a special invitation to save a total of 20 ... avoid serious complications that can result from certain other illnesses or health conditions. ...
... , , , ... revealing that ten percent of Americans face dangerous drinking water, the Water ... their homes. , , On Sunday, the newspaper reported ... on "toxic waters." Among its findings: , , ...
... WILMINGTON, Del., Sept. 14 The airline and pharmaceutical industries ... can be dangerous if the risks are not properly calculated and ... experience of people who make and fly airplanes? , , ... a recent webinar on the topic - Captain Ben Berman, senior ...
... , , , ... today announced it has received the Frost & Sullivan 2009 ... of the Year Award . The award highlights PolyOne,s continuous innovations ... Walter Ripple, general manager, PolyOne,s GLS Thermoplastic Elastomers (TPEs), ...
... CHERRY HILL, N.J., Sept. 14 Nuvilex, Inc. (OTC Bulletin ... sponsored research studies indicate that Oraphyte(TM) can control nematode infestation ... coming months Nuvilex intends to initiate trials on golf course ... most optimal for turfgrass growth. These commercial studies will determine ...
Cached Medicine News:Health News:eClinicalWorks Utilizes EMC to Manage Business Expansion and Reduce Costs 2Health News:eClinicalWorks Utilizes EMC to Manage Business Expansion and Reduce Costs 3Health News:JEWEL-OSCO PHARMACY Offers Grocery Savings to Flu Shot Customers 2Health News:Home Filtering Systems Provide Best Drinking Water Protection 2Health News:Webinar Explores Drug Safety Lessons Pharma Can Learn from Airline Industry 2Health News:PolyOne Presented with Frost & Sullivan Medical Product Award 2Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 2Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 3Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 4
ELISA kit for Varicella-zoster IgM....
ELISA kit for Varicella-zoster IgG....
The DSL-05-10-VZM Varicella Zoster IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Varicella Zoster Virus in human serum. This as...
... Scientific, Inc. Mumps IgG ELISA test system ... Mumps IgG antibody in human serum. When ... of this test, together with other clinical ... immune status, and/or aid in the diagnosis ...
Medicine Products: